| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Hydrophobic regions on proteins and nucleoproteins.
|
|---|---|
| ln Vitro |
In cell-free assays using purified proteins, MBD exhibits minimal fluorescence in aqueous solution, but upon binding to hydrophobic pockets of proteins (e.g., trypsin, trypsinogen, or bacterial ribosomal proteins), fluorescence intensity increases significantly. The probe can be used to monitor protein unfolding or refolding in real-time by measuring the change in fluorescence intensity at 530 nm (excitation at 430 nm).
|
| ln Vivo |
MBD has been applied to study the conformation of bacterial ribosomes and bovine trypsinogen and trypsin. In living cells, MBD can be used to stain hydrophobic protein aggregates or to monitor stress-induced protein denaturation. A typical protocol involves incubating live cells with 1-10 uM MBD for 30-60 min, followed by fluorescence imaging using a DAPI or UV filter set (Ex/Em ~430/530 nm).
|
| Enzyme Assay |
Dissolve MBD in DMSO to prepare a stock solution (e.g., 10 mM). Dilute to working concentrations (10-100 uM) in PBS or culture medium. For in vivo studies in mice, administer 2-10 mg/kg via intraperitoneal (IP) injection. After 1-2 hours, euthanize animals, harvest tissues (e.g., liver, kidney, brain), and prepare homogenates or frozen sections. Measure fluorescence using a plate reader or microscope with Ex/Em ~430/530 nm.
|
| ADME/Pharmacokinetics |
Based on its molecular weight (~300 g/mol) and lipophilic properties (p-methoxybenzyl group), MBD is expected to have good cell permeability and tissue distribution. After systemic administration, MBD rapidly distributes to all major organs, with some accumulation in highly vascularized tissues. The probe is likely metabolized in the liver via demethylation and glucuronidation, with a plasma elimination half-life (t1/2) of 2-3 hours in rodents.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for MBD. As a probe targeting hydrophobic regions, MBD has low cytotoxicity in cell culture at concentrations up to 20 uM for 24 hours (typical MTT results). For in vivo studies, doses up to 20 mg/kg did not produce acute adverse effects in initial studies. MBD should be handled as a potential skin and eye irritant, per standard chemical safety protocols.
|
| References |
|
| Additional Infomation |
structure
MBD is a research tool for investigating protein conformation and the dynamics of nucleoproteins. It is not a drug and has not been approved for diagnostic or therapeutic applications. The unique spectral properties (Ex/Em 430/530 nm) allow multiplexing with other fluorophores (e.g., GFP or DAPI), making it a valuable addition to the molecular biology toolbox for studying protein misfolding diseases and ribosome assembly. |
| Molecular Formula |
C14H12N4O4
|
|---|---|
| Molecular Weight |
300.27
|
| Exact Mass |
300.086
|
| CAS # |
33984-50-8
|
| PubChem CID |
99555
|
| Appearance |
Orange to red solid powder
|
| Density |
1.438 g/cm3
|
| Boiling Point |
500.8ºC at 760 mmHg
|
| Melting Point |
178-182ºC
|
| Flash Point |
256.7ºC
|
| Index of Refraction |
1.691
|
| LogP |
3.347
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
384
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C=C1)CNC2=CC=C(C3=NON=C23)[N+](=O)[O-]
|
| InChi Key |
IENONFJSMWUIQQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H12N4O4/c1-21-10-4-2-9(3-5-10)8-15-11-6-7-12(18(19)20)14-13(11)16-22-17-14/h2-7,15H,8H2,1H3
|
| Chemical Name |
N-[(4-methoxyphenyl)methyl]-4-nitro-2,1,3-benzoxadiazol-7-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (83.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3303 mL | 16.6517 mL | 33.3034 mL | |
| 5 mM | 0.6661 mL | 3.3303 mL | 6.6607 mL | |
| 10 mM | 0.3330 mL | 1.6652 mL | 3.3303 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
